Xu, Qinyang <br/><br/>
MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.  [electronic resource] 

 -  EBioMedicine  Jan 2020 
 - 102609 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2352-3964 
<br/><br/><label>Standard No.: </label>10.1016/j.ebiom.2019.102609  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cohort Studies<br/>Disease Progression<br/>E2F1 Transcription Factor--metabolism<br/>Endometrial Neoplasms--genetics<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Gene Knockdown Techniques<br/>Humans<br/>Mechanistic Target of Rapamycin Complex 1--metabolism<br/>Mechanistic Target of Rapamycin Complex 2--metabolism<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Middle Aged<br/>Models, Biological<br/>Multivariate Analysis<br/>Naphthyridines--pharmacology<br/>Prognosis<br/>Protein Binding--drug effects<br/>Protein Serine-Threonine Kinases--metabolism<br/>Signal Transduction--drug effects<br/>TOR Serine-Threonine Kinases--metabolism<br/>Transcriptional Activation--drug effects<br/>mTOR Associated Protein, LST8 Homolog--metabolism